Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
12.55
+1.39 (12.46%)
At close: Aug 25, 2026, 4:00 PM EDT
12.55
0.00 (0.00%)
After-hours: Aug 25, 2026, 4:00 PM EDT
Eikon Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
PARP1-selective inhibitors are positioned to address the hematologic toxicity of first-gen PARP inhibitors, enabling higher dosing, longer treatment, and more combination options. Eikon's clinical programs show promising early safety and efficacy, with key data to be presented at ESMO. Werner helicase inhibitors offer a new approach for MSI tumors, emphasizing disease control and tolerability.